Introduction
Schizophrenia is one of the most common psychotic disorders. The 1-month prevalence of schizophrenia in the mainland Chinese population is 0.78% according to an epidemiologic study conducted in four provinces. 1 Antipsychotics have been the mainstay of treatment for schizophrenia.
Paliperidone, also referred to as 9-hydroxyrisperidone, is the major active metabolite of risperidone. 2 The mechanism of action of paliperidone is unknown; however, it is known that it acts as an antagonist at dopamine-2 (D 2 ) receptors and 5-hydroxytryptamine 2A (5-HT 2A ) receptors, with a higher affinity for 5-HT 2A receptors
Methods

Data search
PubMed, Embase, and Cochrane Library databases and the Cochrane Controlled Trials Register of paliperidone ER or PP for schizophrenia in Chinese population were searched, as well as Chinese databases of China National Knowledge Infrastructure (CNKI) (http://www.cnki.net), Wanfang data (http://www.wanfangdata.com.cn) and CBM/VIP information (http://www.cqvip.com). The search included all clinical studies published between January 1, 2008, and May 22, 2015 (search date), supplemented by hand search of academic dissertations and several key literature sources. The search was conducted using several types of key terms, categories of country or region, disease classification, and treatment. For the category of country or region, the key terms were "China", "Chinese", "Taiwan", "Taiwanese", and "Hong Kong". For the category of disease classification, the search term was "schizophrenia". For the category of treatment, the key terms were "paliperidone", "9-OH risperidone", "Invega", and "Sustenna". For all the databases, search terms within each category were combined by using the Boolean operator OR. Categories were then combined by using the Boolean operator AND.
Study selection
Chinese language studies included in this review were restricted to the Chinese core medical journals, based on the Guide of Core Journal of China (2011 version) published by Peking University Press. 6 The study participants were residents of the People's Republic of China, Taiwan, or Hong Kong, with a diagnosis of schizophrenia by any criteria, irrespective of age or sex. The types of intervention were paliperidone ER or PP. The included studies also had to report numerical data on at least one recognized outcome measure related to efficacy, effectiveness, or safety/tolerability. Studies were excluded if they were duplicate publications, or had no numerically reportable data on at least one relevant outcome measure. Case reports, narrative reviews, editorials, letters to the editor, or publications that did not include any formulation of paliperidone as the intervention were also excluded.
Results
Results of the search
A total of 122 publications were retrieved from the literature databases ( Figure 1 ). Sixty of these were excluded because they did not meet the criteria of study selection. In addition, a publication about the pharmacokinetics of paliperidone ER conducted in healthy Chinese subjects, which was omitted in the initial electronic search, was added manually. A total of 63 publications were finally included in the review. Detailed information of the 63 publications are cited in Supplementary material.
Characteristics of the studies
Among the 63 publications included in the review, 53 were related to paliperidone ER, nine were related to PP, and one study compared paliperidone ER and PP. Most paliperidone ER-related publications were interventional studies, including 34 randomized controlled trials (RCTs) and 17 open-label, single-arm studies. Of the two nonintervention studies, one was observational, and the other a pharmacokinetic study. Of the nine PP-related studies, four were RCTs, three were observational studies, and two studies assessed the pharmacokinetics of PP in patients with schizophrenia.
These publications were published in either international peer-reviewed journals (publications in English, n=15) or Chinese core journals (publications in Chinese, n=48).
Paliperidone eR Pharmacokinetic characteristics
Only one study had been performed to assess the pharmacokinetics of paliperidone ER in healthy Chinese subjects. This was a single-center, double-blind, randomized, single-dose study. A total of 24 healthy Han Chinese subjects (13 men, eleven women), aged 19-35 years, were randomly assigned in a 1:1 ratio to receive either paliperidone ER 3 or 9 mg. Mean t max and t 1/2 were 22.2 and 22.8 hours for the 3 mg group, and 24.8 and 21.4 hours for the 9 mg group. Similar to the pharmacokinetic data reported for the Caucasian population, the pharmacokinetics of paliperidone ER in the Chinese population can be adequately described by a one-compartment pharmacokinetic model, and is linearly related to dose. Based on these data, paliperidone ER is suitable to be taken once daily in the morning.
Efficacy outcomes
The efficacy of paliperidone ER in Chinese patients was assessed in 35 comparative studies (Table 1 ) and 17 single-arm studies. All the drugs used for comparison were atypical oral antipsychotics, mostly risperidone (n=13) and olanzapine (n=9), followed by aripiprazole (n=3), ziprasidone (n=2), and clozapine (n=2).
The mean change in Positive and Negative Syndrome Scale (PANSS) total scores compared with baseline was the most commonly reported symptom outcome. The overall findings from comparative studies and single-arm studies were consistent: paliperidone ER treatment was associated with statistically significant reductions in PANSS total 
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Systematic review of paliperidone in the Chinese population scores. The median change in PANSS total score was -38.60 in RCTs, and -34.48 in single-arm studies. In almost twothird of RCTs (21/33), the relative reduction in PANSS total score at the end point was .40%. Response rate was also a commonly used item to identify symptom outcome, but the definitions were different, and it was difficult to unify the definition of response.
Most of these studies were short-term studies, with duration of 4-12 weeks. Only three studies evaluated the longterm efficacy and safety of paliperidone ER: the duration of one study was 6 months, and that of the other two was 1 year. [8] [9] [10] The results were consistent with other international data. Paliperidone ER was efficacious in the long term and significantly delayed relapse in Chinese patients with schizophrenia. No new safety signals were detected.
Onset of action
Consistent results reported that paliperidone ER has a much more rapid onset of action than risperidone or olanzapine in the first week ( Table 2 ). Eight RCTs presented PANSS or Brief Psychiatric Rating Scale (BPRS) total score data in week 1; three of these compared the data for paliperidone ER with that for risperidone, and five compared the data for paliperidone ER with that for olanzapine. In all these eight studies, paliperidone ER effected significant reduction in PANSS total score at week 1 compared with that at baseline. The paliperidone ER group achieved lower PANSS or BPRS total score at week 1 in all studies compared with risperidone (3/3, P,0.05), and in most studies compared with olanzapine (3/5, P,0.05). Paliperidone ER treatment also resulted in significantly lower PANSS or BPRS total scores compared with risperidone in week 2; however, the results were comparable with those for olanzapine. There was not enough information to determine the dose details in week 1 and week 2, but the OROS ® technology of paliperidone ER allowed initiation with effective dosage, which could benefit the onset.
effectiveness outcomes
Seventeen comparative studies and 12 single-arm studies reported effectiveness outcomes, including functionality, neurocognitive function, and quality of life. The most commonly used effectiveness assessment was the Personal and Social Performance Scale (PSP) to assess functionality. Eleven comparative studies and ten single-arm studies reported PSP outcome. Paliperidone ER treatment significantly improved the PSP score at the end point compared with that at baseline in all these studies (Table 3) . In all eleven comparative studies, paliperidone ER resulted in significantly better PSP scores at the end point than those achieved with comparative drugs, including risperidone, olanzapine, and aripiprazole.
Three comparative studies and three single-arm studies reported neurocognitive function outcome, [11] [12] [13] [14] [15] [16] assessed by different tools including the Wisconsin Card Sorting Test, Wechsler Memory Scale-Revised, Stroop, or Measurement and Treatment Research to Improve Cognition in Schizophrenia initiative -Consensus Cognitive Battery. Neurocognitive outcome was the primary outcome in one comparative study and three single-arm studies. In all these studies, paliperidone ER treatment significantly improved neurocognitive function at the end point compared with that at baseline.
Quality of life was assessed in four trials, 12,17-19 using different tools including the Short Form-36 Health Survey, The World Health Organization Quality of Life 100, Social Disability Screening Schedule, and Overall Quality of Life Rating Scale. In all these studies, paliperidone ER treatment significantly improved the quality of life at the end point compared with that at baseline.
Safety and tolerability
Safety and tolerability outcome was reported in most studies. The most commonly reported treatment-emergent adverse events (TEAEs) were extrapyramidal symptoms (EPSs), insomnia or somnolence, and prolactin-related TEAEs. Paliperidone ER was generally well tolerated in the Chinese population, and no special safety signal was found.
extrapyramidal symptoms EPSs were the most frequently reported TEAE reported in these articles as EPS, akathisia, dyskinesia, tumor, dystonia, and Parkinsonism. The incidence of EPSs associated with paliperidone ER treatment was lower than that with risperidone treatment but higher than that with olanzapine treatment.
Prolactin elevation
Six RCTs and three single-arm studies tested plasma prolactin level; the study duration ranged from 4 to 12 weeks. Paliperidone ER significantly increased plasma prolactin level compared with that at baseline. The prolactin level in the paliperidone ER group was significantly lower than that in the risperidone group but higher than that in the olanzapine and aripiprazole groups. The potential prolactinrelated TEAEs were not especially reported in most studies. In five studies that reported potential prolactin-related TEAEs, including irregular menstruation, amenorrhea, galactorrhea, and gynecomastia, the total incidence was 0%-5%. 
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Zhang et al weight and metabolic parameters Eight RCTs and four single-arm studies reported outcomes related to weight gain and metabolic parameters. Most of the studies had a duration of 6-12 weeks, except a 52-week study. The most commonly assessed metabolic parameters were levels of glucose and lipids in plasma. In the 6-to 12-week studies, paliperidone ER treatment resulted in an insignificant change or significant but mild change in mean weight. Paliperidone ER treatment caused no significant change in blood glucose levels. In most studies, paliperidone ER treatment caused no significant change in lipid metabolism, although some studies showed a small increase in triglyceride levels. Generally, in these short-duration studies, paliperidone ER was well tolerated in terms of effect on weight and metabolic parameters, and had some advantage over olanzapine in terms of weight gain, and glucose and lipid metabolism.
21,22,24
Paliperidone palmitate PP-related studies in the Chinese population included two pharmacokinetic studies, four comparative studies, and three single-arm studies. Among the pharmacokinetic studies, the first one was an open-label, randomized, parallel-group, multicenter study in patients with chronic schizophrenia. 25 On day 1, 48 eligible subjects were randomly assigned in a 1:1:1 ratio to 25, 100, or 150 mg PP groups; the same dose as that assigned on day 1 was injected on day 8 on the other side of the gluteal muscle. The plasma concentrations of paliperidone gradually increased to a C max at a mean t max of 13 days. The area under the curve (AUC) (0-35 days), AUC (0-210 days), and AUC (0-∞) for the three doses were dose-proportional. The median half-life (t 1/2 ) ranged from 42 to 77 days, and the t 1/2 was prolonged for higher doses. The therapeutic regimen for PP in this study was different from the recommended regimen. The second study was designed to evaluate the pharmacokinetics of PP after multiple doses (the recommended dosing regimen): 150 mg on day 1, followed by 100 mg on day 8. 26 Thereafter, a flexible dose (75, 100, or 150 mg) was administered monthly, based on the patient's response, consecutively for 6 months. The mean C max was 17-25 ng/mL at a mean t max of 11-17 days. Based on these data, the pharmacokinetic characteristics of PP in the Chinese population were similar to those found in studies on the Caucasian population. 27, 28 The first comparative study was a registration study of PP for its introduction to the Chinese market. 29 It was a noninferiority-design, open-label, rater-blinded, parallelgroup, 13-week study. The active comparator was risperidone long-acting injectable (RIS-LAI, 25-50 mg/2 weeks). A significant improvement with respect to baseline was observed at the end point for both groups; mean (standard deviation) change from baseline to end point in PANSS total scores was -23.6 (16.28) for the PP group and -26.9 (15.43) for the RIS-LAI group. The mean change in PSP was 16.8 (PP group) and 18.6 (RIS-LAI group), and the overall incidence of TEAEs was not different between the groups.
Three subsequent small sample size, open-label, randomized, comparative studies of PP and oral risperidone were conducted with the recommended initiation dosing regimen for PP over durations of 6, 8, and 12 weeks. [30] [31] [32] The mean change from baseline to end point in PANSS total score and the tolerability were comparable between both groups. A total of three single-arm studies of PP was conducted to establish the effects of PP on acute or recent-onset patient hospitalization rates. [33] [34] [35] The results showed that PP treatment significantly (P,0.0001) reduced both the number of hospitalizations and the number of days spent in the hospital. The most frequently reported TEAEs were injection-site pain, EPSs, akathisia, and insomnia.
Discussion
This study was a systematic review carried out to critically evaluate the efficacy, effectiveness, and safety of paliperidone (as the oral ER and 1-month long-acting injection formulations) in the Chinese population. The results demonstrated that the efficacy of paliperidone ER was at least comparable with that of other atypical antipsychotics, which was consistent with the results of the latest meta-analysis of Chinese patients with schizophrenia. 36 The onset of symptom control was faster in the paliperidone ER group, compared with the risperidone group at week 1 and week 2, and the olanzapine treatment at week 1. This may be because the OROS ® technology and pharmacokinetic profile of paliperidone ER allow once-daily dosing with an initial dose of 6 mg and no need for initial dose titration, which enables rapid action. A review summarized the time required to achieve significant alleviation of psychiatric symptoms compared with baseline; 37 paliperidone ER and risperidone showed alleviation of symptoms from day 4, while olanzapine, aripiprazole, and ziprasidone took 1-2 weeks. However, there were no available head-to-head comparison results. Our findings could help to enrich the data on antipsychotic onset of action. Paliperidone was well tolerated in the Chinese population, and no special safety issues were found. The incidence of EPSs and increase in prolactin levels associated with paliperidone ER treatment were lower than that with risperidone treatment but higher than that with olanzapine treatment. This was consistent with the result of other studies.
Paliperidone ER treatment resulted in a significantly better PSP score at the end point compared with other antipsychotics 
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Systematic review of paliperidone in the Chinese population including risperidone, olanzapine, and aripiprazole. This was a novel finding of our systematic review. There are a limited number of randomized controlled studies comparing paliperidone ER and other antipsychotics in international publications. No RCTs have compared the functionality outcome between paliperidone ER and risperidone or aripiprazole. Three 6-week studies identified the efficacy and safety of paliperidone ER, and used olanzapine 10 mg/d treatment to confirm trial validity; the pooled data showed that there was no significant difference in mean PSP score change from baseline to end point between paliperidone ER and olanzapine groups. A period of 6 weeks may not be enough to test the functionality outcome, as it is influenced by several factors, including not only positive symptoms but also negative symptoms, affective symptoms, cognitive symptoms, and side effects such as sedation and metabolic syndrome. [38] [39] [40] [41] [42] The efficacy of paliperidone ER is at least comparable to that of other antipsychotics, and it has a better safety profile than risperidone, and less severe sedative and metabolic effects than olanzapine. This might be the reason for the better functionality outcome of paliperidone ER treatment found in our review. However, the sample size of studies included in this systematic review is relatively small, and PSP is not the primary end point in most studies, so the effectiveness of antipsychotics in functionality improvement still needs further verification in the future. Results from studies on PP demonstrated that it is an effective and welltolerated treatment for Chinese patients with schizophrenia, and may have some advantage in terms of functionality and patient's medication satisfaction compared with the oral formulation. Additionally, several studies have demonstrated that LAI has an advantage over oral antipsychotics in preventing relapse, and in reducing hospitalization rate and number of hospitalization days. 34, 43, 44 The studies on PP were fewer than those on paliperidone ER; a People's Republic of China international survey in 2012 showed that only 2.75% of patients with schizophrenia use LAI antipsychotics, and only 0.48% use atypical LAIs. 45 Both LAI data on clinical research and LAI usage in clinical practice need to be improved in the People's Republic of China.
There were some problems related to study quality, especially with publications from Chinese core journals. Most of the RCTs from Chinese core journals in this review did not clearly elucidate the methods of randomization, or information about blinding. Some studies did not give detailed information about mean dose, which caused difficulty in comparing between different treatment arms. The duration of most studies was 6-12 weeks; long-term studies were relatively fewer. Additionally, the sample sizes of some studies were relatively small.
Conclusion
Paliperidone is one of the first-line antipsychotics used in the People's Republic of China. Both paliperidone ER and PP are effective, safe, and well tolerated in Chinese patients with schizophrenia according to the data we reviewed. Paliperidone may have some advantage over other antipsychotics in terms of onset of action and functionality improvement. Future studies could focus more on long-term data and LAI treatment.
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